Meeting Overview - The first extraordinary general meeting of Maito Co., Ltd. (stock code: 301006) was held on September 15, 2025, to review and approve several important proposals [1] - The meeting combined on-site voting and online voting, presided over by Chairman Sun Weiguo [1] Attendance and Voting - The meeting took place at 14:30 in Nanjing, Jiangsu Province, with a total of 23 shareholders participating, representing 79,707,800 shares, which is 57.9266% of the total voting shares [2] - Among the participants, 7 shareholders voted on-site, representing 79,639,800 shares (57.8772%), while 16 shareholders voted online, representing 68,000 shares (0.0494%) [2] - A total of 18 minority shareholders participated, representing 4,731,600 shares (3.4386%) [2] Proposal Review and Voting Results - The meeting reviewed two main categories of proposals: 1. Amendments to the Articles of Association and related documents, including the rules for shareholder meetings, board meetings, and the abolition of the supervisor meeting rules. The voting results showed 79,669,200 shares in favor (99.9516%), 37,200 shares against (0.0467%), and 1,400 shares abstaining (0.0018%) [3] 2. Proposals for the formulation and revision of certain company systems, which received similar voting results as the amendments to the Articles of Association, all being approved [3] Legal Opinion - Lawyers from Jiangsu Century Tongren Law Firm confirmed that the meeting's convening and procedures complied with relevant laws, regulations, and the company's Articles of Association, deeming the resolutions valid [4]

Group 1 - The company announced the approval of new and revised governance systems to enhance internal governance mechanisms [1] - The board of directors held a meeting on August 28, 2025, to review and pass the proposal for the establishment and revision of relevant systems [1] - The revisions are based on the latest regulations and guidelines, including the Company Law, Securities Law, and Shenzhen Stock Exchange rules [1] Group 2 - Specific systems being revised or established include the management system for preventing the occupation of funds by controlling shareholders and the management system for directors and senior management holding and trading company stocks [1] - The proposed revisions and new systems will require approval at the company's first extraordinary general meeting in 2025 to take effect [1]

Core Points - The company has undergone a change in its actual controller, with a 2% equity transfer from Chongqing Chemical Medicine Holdings to China General Technology Group [5][6][7][8] - The company has approved a share repurchase plan during the board meeting held on July 10, 2025, which was subsequently ratified by the shareholders [8][10] - The company has also reported the release of pledged shares by its controlling shareholder, involving 109,867,400 shares [8][9] Company Overview - The company is identified as Chongqing Pharmaceutical Holdings, with the stock code 000950 [1] - The board of directors has confirmed that all members attended the meeting to review the report [2] - The company has not proposed any cash dividends or stock bonuses for the reporting period [3] Financial and Operational Highlights - The company has not experienced any changes in its controlling shareholder during the reporting period [5] - The company has completed the necessary registration procedures for the equity transfer related to the change in actual controller [7] - The board has approved the 2025 semi-annual report and its summary [24][25]

Core Viewpoint - The board of directors of Ji'an Mankun Technology Co., Ltd. approved several resolutions during the fifth meeting of the third board, including adjustments to the stock incentive plan and revisions to company regulations [1][2][5]. Group 1: Board Meeting Details - The board meeting was held on July 29, 2025, with all seven directors present, and it complied with relevant laws and regulations [1]. - The meeting was chaired by Chairman Hong Jun Cheng, and all supervisors and senior management attended [1]. Group 2: Stock Incentive Plan Adjustments - The grant price for the 2023 restricted stock incentive plan was adjusted from 14.43 yuan per share to 14.01 yuan per share due to the completion of the 2024 annual equity distribution [1][2]. - A total of 186,297.2 thousand shares of unvested restricted stock were canceled due to performance metrics not being met and the departure of 15 incentive targets [2]. Group 3: Company Regulation Revisions - The board approved revisions to various company regulations, including the Articles of Association and several management systems, with unanimous support from all directors [5][6]. - The proposed changes will be submitted for approval at the upcoming shareholders' meeting scheduled for August 14, 2025 [6].